Abiopharma

News list

(99% Neutral) Genmab (GMAB) Announces Clinical Development Update (Form 6-K)

Full text

News bot Oct. 18, 2025, 5:27 p.m.
🌍 Genmab (GMAB) - Form 6-K Filing

Filing Date: 2022-06-09

Accepted: 2022-06-09 17:22:35

Event Type: Clinical Trial Update

Event Details:

Genmab AS (Nasdaq GMAB) has commenced a new arbitration under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab. This new arbitration follows from the award in the prior arbitration. In this new arbitration, Genmab is consequently seeking an award of $405 million.
💼 Business Developments:
- ✅ Partnership/Collaboration
- ❌ Acquisition Activity: Not reported
- ✅ Licensing Agreement
- ❌ Regulatory Milestone: Not reported
- ❌ Leadership Updates: Not reported
📞 Contact Information:
- Email: mmp@genmab.com